Contemporary Trends in High-Potency P2Y12 Receptor Inhibitor Use Among Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

BACKGROUND: High-potency P2Y12 receptor inhibitors (ticagrelor and prasugrel) reduce ischemic outcomes compared with clopidogrel among patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). This study aims to examine contemporary trends and identify predictors of their use among patients with AMI undergoing PCI in the United States. METHODS: This observational study used electronic health records from >95 US-based health care organizations. Adults with AMI who underwent PCI between 2016 and 2023 were included. The primary outcome was the prescription of high-potency P2Y12 receptor inhibitors versus clopidogrel. Multivariable logistic regression was used to identify independent predictors of P2Y12 inhibitor selection. RESULTS: Among 182986 patients with AMI who underwent PCI, clopidogrel was the most prescribed P2Y12 receptor inhibitor (101136 patients, 55.2%), followed by ticagrelor (68350, 37.4%) and prasugrel (13500, 7.4%). Clopidogrel use declined from 66.2% in 2016 to 51.4% in 2023 (P_trend=0.002), whereas ticagrelor use increased from 27.8% to 39.4% (P_trend=0.022), and prasugrel use increased from 6.0% to 9.2% (P_trend=0.008), predominantly after 2019. High-potency P2Y12 receptor inhibitors were more frequently used in younger patients (<60years), those with prior PCI, prior MI, chronic kidney disease, and morbid obesity. CONCLUSIONS: Among patients with AMI undergoing PCI, the use of high-potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR-REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice.